Switch theme
Sign up to access all valuation multiples
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
2012
163
LTM Revenue $111M
LTM EBITDA n/a
$74.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prothena Corp. has a last 12-month revenue of $111M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Prothena Corp. achieved revenue of $135M and an EBITDA of -$154M.
Prothena Corp. expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prothena Corp. valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $91.4M | $135M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$190M | -$154M | XXX | XXX | XXX |
| EBITDA Margin | -208% | -114% | XXX | XXX | XXX |
| Net Profit | -$117M | -$147M | XXX | XXX | XXX |
| Net Margin | -128% | -109% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Prothena Corp.'s stock price is $10.
Prothena Corp. has current market cap of $535M, and EV of $74.5M.
See Prothena Corp. trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $74.5M | $535M | XXX | XXX | XXX | XXX | $-2.65 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Prothena Corp. has market cap of $535M and EV of $74.5M.
Prothena Corp.'s trades at 0.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Prothena Corp.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Prothena Corp. and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $74.5M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | XXX | XXX |
| P/E | -4.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpProthena Corp.'s NTM/LTM revenue growth is -37%
Prothena Corp.'s revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $1.8M for the same period.
Over next 12 months, Prothena Corp.'s ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Prothena Corp.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Prothena Corp. and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 48% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -114% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -151% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 50% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 165% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 214% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prothena Corp. acquired XXX companies to date.
Last acquisition by Prothena Corp. was XXXXXXXX, XXXXX XXXXX XXXXXX . Prothena Corp. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Prothena Corp. founded? | Prothena Corp. was founded in 2012. |
| Where is Prothena Corp. headquartered? | Prothena Corp. is headquartered in United States of America. |
| How many employees does Prothena Corp. have? | As of today, Prothena Corp. has 163 employees. |
| Who is the CEO of Prothena Corp.? | Prothena Corp.'s CEO is Dr. Gene G. Kinney, PhD. |
| Is Prothena Corp. publicy listed? | Yes, Prothena Corp. is a public company listed on NAS. |
| What is the stock symbol of Prothena Corp.? | Prothena Corp. trades under PRTA ticker. |
| When did Prothena Corp. go public? | Prothena Corp. went public in 2012. |
| Who are competitors of Prothena Corp.? | Similar companies to Prothena Corp. include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Prothena Corp.? | Prothena Corp.'s current market cap is $535M |
| What is the current revenue of Prothena Corp.? | Prothena Corp.'s last 12-month revenue is $111M. |
| What is the current EV/Revenue multiple of Prothena Corp.? | Current revenue multiple of Prothena Corp. is 0.7x. |
| What is the current revenue growth of Prothena Corp.? | Prothena Corp. revenue growth between 2023 and 2024 was 48%. |
| Is Prothena Corp. profitable? | Yes, Prothena Corp. is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
